Alfa Injection

Approx. Rs 42,000 / PieceGet Latest Price

• Each pack contains:

  • 1 vial of powder (Eptacog Alfa, human recombinant activated coagulation factor VII).

  • 1 pre-filled syringe of solvent with a separate plunger rod.

  • Vial adapter for reconstitution (Novo Nordisk).

• Formulation:

  • Human recombinant coagulation factor VIIa (activated), produced from r-DNA technology.

  • Powder and solvent for preparing a solution for intravenous (IV) injection.

• Indication:

  • Treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or IX.

  • Used in rare bleeding disorders (e.g., acquired hemophilia) or during surgical procedures to control bleeding.

• Mechanism of Action:

  • Eptacog Alfa activates factor X in the coagulation cascade, bypassing the need for factor VIII or IX.

• Administration:

  • Requires reconstitution using the provided solvent and vial adapter.

  • Administered by intravenous injection.

• Storage:

  • Powder: Store in a refrigerator (2°C to 8°C / 36°F to 46°F).

  • Solvent: Can be stored at room temperature.

  • Do not freeze.

• Side Effects:

  • Risk of thromboembolic events (blood clots).

  • Possible allergic reactions (rash, fever, or swelling).

  • Injection site reactions.

• Manufacturer: Produced by Novo Nordisk under the brand name Novoseven®.

• Clinical Benefits:

  • Effective in controlling bleeding in patients with factor inhibitors.

  • Can be used for prophylaxis to prevent bleeding episodes in certain patients.

• Approval: Approved for use in multiple countries for patients with hemophilia and other bleeding disorders.

Approx. Rs 4,500 / PieceGet Latest Price

• Active Ingredient: Turoctocog Alfa (recombinant human coagulation factor VIII)

• Indication: Treatment and prevention of bleeding episodes in hemophilia A (factor VIII deficiency)

• Mechanism of Action: Replaces missing or deficient factor VIII to support blood clotting

• Formulation: 250 IU vial, for intravenous (IV) administration

• Purity: Recombinant product, reducing the risk of viral contamination

• Administration: Reconstituted with sterile diluent, injected via IV

• Dosage: Tailored to the patient’s weight, severity of hemophilia, and bleeding episodes

• Common Side Effects: Allergic reactions (rash, itching), development of inhibitors

• Storage: Refrigerate (2°C to 8°C / 36°F to 46°F), protect from light, do not freeze

• Prophylactic Use: Reduces frequency of bleeding episodes and improves quality of life

• Manufacturer: Novo Nordisk

• Approval: Approved for use in various countries for hemophilia A management